Literature DB >> 10340280

The Danish Osteoporosis Prevention Study (DOPS): project design and inclusion of 2000 normal perimenopausal women.

L Mosekilde1, A P Hermann, H Beck-Nielsen, P Charles, S P Nielsen, O H Sørensen.   

Abstract

OBJECTIVE: In 1990 we initiated a 20 year, partly randomised study (Danish Osteoporosis Prevention Study, DOPS) in order to (a) evaluate clinical, biochemical and osteodensitometric variables as predictors of low bone mass and future osteoporotic fractures, and (b) test the hypothesis, that hormone replacement therapy (HRT) initiated shortly after menopause reduces the risk of later osteoporotic fractures. This report describes study design and baseline characteristics of the DOPS-cohort.
METHODS: The study design is pragmatic, attempting to mimic the normal clinical situation. Several HRT alternatives are available according to clinical need. It was considered futile, impractical and unethical to use placebo for 20 years. Instead the study focus on hard endpoints (fractures) confirmed by independent persons (peripheral fractures) or by methods which allow investigator blinding (spinal X-rays). Statistical evaluation will focus on intention to treat analyses evaluating the decision of HRT and it's feasibility. With a compliance of 60% we will have sufficient statistical power (88%) to detect a fracture reduction of 40% in the treatments group. Clinical risk factors, current daily intakes of macronutrients, vitamins and minerals, anthropometric variables, biochemical variables (including bone markers and 25-hydroxyvitamin D), regional bone mineral density (BMD) and total body composition were assessed in all participants at entry and at various follow up intervals.
RESULTS: 2016 study participants were recruited by direct mailing to a random sample of 45-58 years old women. In the randomised arm 501 were allocated to HRT and 505 to no treatment. In the non-randomised arm 219 preferred HRT and 791 preferred no treatment. Post-randomisation analysis revealed a slight but significant difference in age (50.01 versus 50.44 years) but no difference in menopausal age, prevalence of hysterectomy, educational level, BMI, serum bone alkaline phosphatase, serum osteocalcin, urine hydroxyproline or serum 25-hydroxyvitamin D. In the non-randomised arm women preferring HRT were closer to menopause, had a higher prevalence of hysterectomy, were better educated, were leaner, and had lower bone turnover than the women, who refused HRT.
CONCLUSION: It is possible to include a sufficient number of perimenopausal women in a randomised 20 year study on the antifracture effect of HRT.

Entities:  

Mesh:

Year:  1999        PMID: 10340280     DOI: 10.1016/s0378-5122(99)00006-7

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  14 in total

1.  Ten-year prediction of osteoporosis from baseline bone mineral density: development of prognostic thresholds in healthy postmenopausal women. The Danish Osteoporosis Prevention Study.

Authors:  Bo Abrahamsen; Lars Rejnmark; Stig Pors Nielsen; Bo Rud; Nis Nissen; Leif Mosekilde; Olaf Bärenholdt; Jens-Erik Beck Jensen
Journal:  Osteoporos Int       Date:  2005-09-10       Impact factor: 4.507

2.  Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures.

Authors:  Niklas R Jørgensen; Lise B Husted; Kristen K Skarratt; Leanne Stokes; Charlotte L Tofteng; Torben Kvist; Jens-Erik B Jensen; Pia Eiken; Kim Brixen; Stephen Fuller; Rory Clifton-Bligh; Alison Gartland; Peter Schwarz; Bente L Langdahl; James S Wiley
Journal:  Eur J Hum Genet       Date:  2012-01-25       Impact factor: 4.246

3.  Performance of four clinical screening tools to select peri- and early postmenopausal women for dual X-ray absorptiometry.

Authors:  B Rud; J E B Jensen; L Mosekilde; S P Nielsen; J Hilden; B Abrahamsen
Journal:  Osteoporos Int       Date:  2004-09-30       Impact factor: 4.507

Review 4.  Hypovitaminosis D in the elderly: from bone to brain.

Authors:  E P Cherniack; H Florez; B A Roos; B R Troen; S Levis
Journal:  J Nutr Health Aging       Date:  2008 Jun-Jul       Impact factor: 4.075

5.  No effect of vitamin K1 intake on bone mineral density and fracture risk in perimenopausal women.

Authors:  L Rejnmark; P Vestergaard; P Charles; A P Hermann; C Brot; P Eiken; L Mosekilde
Journal:  Osteoporos Int       Date:  2006-05-09       Impact factor: 4.507

6.  Estrogen alone and health outcomes in black women by African ancestry: a secondary analyses of a randomized controlled trial.

Authors:  Rowan T Chlebowski; Wendy Barrington; Aaron K Aragaki; JoAnn E Manson; Gloria Sarto; Mary J OʼSullivan; Daniel Wu; Jane A Cauley; Lihong Qi; Robert L Wallace; Ross L Prentice
Journal:  Menopause       Date:  2017-02       Impact factor: 2.953

7.  Effects of COLIA1 polymorphisms and haplotypes on perimenopausal bone mass, postmenopausal bone loss and fracture risk.

Authors:  N González-Bofill; L B Husted; T Harsløf; C L Tofteng; B Abrahamsen; P Eiken; P Vestergaard; B L Langdahl
Journal:  Osteoporos Int       Date:  2010-06-23       Impact factor: 4.507

8.  Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS).

Authors:  P Vestergaard; P Hermann; J-E B Jensen; P Eiken; L Mosekilde
Journal:  Osteoporos Int       Date:  2011-06-28       Impact factor: 4.507

9.  Polymorphisms in the ALOX12 gene and osteoporosis.

Authors:  T Harsløf; L B Husted; M Nyegaard; M Carstens; L Stenkjær; K Brixen; P Eiken; J-E B Jensen; A D Børglum; L Mosekilde; L Rejnmark; B L Langdahl
Journal:  Osteoporos Int       Date:  2010-11-23       Impact factor: 4.507

10.  Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis.

Authors:  Joyce B J van Meurs; Thomas A Trikalinos; Stuart H Ralston; Susana Balcells; Maria Luisa Brandi; Kim Brixen; Douglas P Kiel; Bente L Langdahl; Paul Lips; Osten Ljunggren; Roman Lorenc; Barbara Obermayer-Pietsch; Claes Ohlsson; Ulrika Pettersson; David M Reid; Francois Rousseau; Serena Scollen; Wim Van Hul; Lidia Agueda; Kristina Akesson; Lidia I Benevolenskaya; Serge L Ferrari; Göran Hallmans; Albert Hofman; Lise Bjerre Husted; Marcin Kruk; Stephen Kaptoge; David Karasik; Magnus K Karlsson; Mattias Lorentzon; Laura Masi; Fiona E A McGuigan; Dan Mellström; Leif Mosekilde; Xavier Nogues; Huibert A P Pols; Jonathan Reeve; Wilfried Renner; Fernando Rivadeneira; Natasja M van Schoor; Kurt Weber; John P A Ioannidis; André G Uitterlinden
Journal:  JAMA       Date:  2008-03-19       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.